A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmacia
Patients are randomized to receive clarithromycin and ethambutol plus either placebo or rifabutin at one of two doses. Treatment continues indefinitely. AS PER AMENDMENT 04/19/94: Doses of rifabutin have been lowered.
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Isoniazid for TB prophylaxis ONLY.
Patients must have:
HIV infection.
MAC infection.
Life expectancy of at least 16 weeks.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Perceived unreliability or unavailability for frequent monitoring.
Concurrent Medication:
Excluded:
Antimycobacterial drugs other than the study drugs.
Carbamazepine.
Terfenadine.
Theophylline.
Patients with the following prior condition are excluded:
History of hypersensitivity to rifabutin, rifampin, erythromycin, clarithromycin, azithromycin, or ethambutol.
Prior Medication:
Excluded within 7 days prior to study entry:
Rifabutin.
Rifampin.
Ethionamide.
Cycloserine.
Clofazimine.
Ethambutol.
Amikacin.
Ciprofloxacin.
Ofloxacin.
Sparfloxacin.
Azithromycin.
Clarithromycin.
Pyrazinamide.
Excluded within 14 days prior to study entry:
Carbamazepine.
Terfenadine.
Theophylline.
Clareo Health | A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
